While reporting financial results for the second quarter on Tuesday, medical devices company AngioDynamics, Inc. (ANGO) maintained its adjusted loss guidance for the full year 2026, while raising annual net sales outlook.For fiscal 2026, the company continues to project adjusted loss in the range of $0.33 to$0.23 per share, raised its net sales guidance to between $312 million and$314 million from the prior forecast between $308 million and$313 million.On average, four analysts polled by Thomson Reuters ...